Hippocampo-Horn Percentage and Parietal Atrophy Score for Easy Visual Assessment of Brain Atrophy on Magnetic Resonance Imaging in Early- and Late-Onset Alzheimer's Disease.

Early-onset Alzheimer’s disease hippocampo-horn percentage late-onset Alzheimer’s disease mediotemporal atrophy parietal atrophy parietal atrophy score reliability

Journal

Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863

Informations de publication

Date de publication:
2021
Historique:
pubmed: 12 10 2021
medline: 20 1 2022
entrez: 11 10 2021
Statut: ppublish

Résumé

Magnetic resonance imaging (MRI) visual scales of brain atrophy are important for differential diagnosis of dementias in routine clinical practice. Atrophy patterns in early- and late-onset Alzheimer's disease (AD) can be different according to some studies. Our goal was to assess brain atrophy patterns in early- and late-onset AD using our recently developed simple MRI visual scales and evaluate their reliability. We used Hippocampo-horn percentage (Hip-hop) and Parietal Atrophy Score (PAS) to compare mediotemporal and parietal atrophy on brain MRI among 4 groups: 26 patients with early-onset AD, 21 younger cognitively normal persons, 32 patients with late-onset AD, and 36 older cognitively normal persons. Two raters scored all brain MRI to assess reliability of the Hip-hop and PAS. Brain MRIs were obtained from Alzheimer's Disease Neuroimaging Initiative (ADNI) database. The patients with early-onset AD had significantly more pronounced mediotemporal and also parietal atrophy bilaterally compared to the controls (both p < 0.01). The patients with late-onset AD had significantly more pronounced only mediotemporal atrophy bilaterally compared to the controls (p < 0.000001), but parietal lobes were the same. Intra-rater and inter-rater reliability of both visual scales Hip-hop and PAS were almost perfect in all cases (weighted-kappa value ranged from 0.90 to 0.99). While mediotemporal atrophy detected using Hip-hop is universal across the whole AD age spectrum, parietal atrophy detected using PAS is worth rating only in early-onset AD. Hip-hop and PAS are very reliable MRI visual scales.

Sections du résumé

BACKGROUND
Magnetic resonance imaging (MRI) visual scales of brain atrophy are important for differential diagnosis of dementias in routine clinical practice. Atrophy patterns in early- and late-onset Alzheimer's disease (AD) can be different according to some studies.
OBJECTIVE
Our goal was to assess brain atrophy patterns in early- and late-onset AD using our recently developed simple MRI visual scales and evaluate their reliability.
METHODS
We used Hippocampo-horn percentage (Hip-hop) and Parietal Atrophy Score (PAS) to compare mediotemporal and parietal atrophy on brain MRI among 4 groups: 26 patients with early-onset AD, 21 younger cognitively normal persons, 32 patients with late-onset AD, and 36 older cognitively normal persons. Two raters scored all brain MRI to assess reliability of the Hip-hop and PAS. Brain MRIs were obtained from Alzheimer's Disease Neuroimaging Initiative (ADNI) database.
RESULTS
The patients with early-onset AD had significantly more pronounced mediotemporal and also parietal atrophy bilaterally compared to the controls (both p < 0.01). The patients with late-onset AD had significantly more pronounced only mediotemporal atrophy bilaterally compared to the controls (p < 0.000001), but parietal lobes were the same. Intra-rater and inter-rater reliability of both visual scales Hip-hop and PAS were almost perfect in all cases (weighted-kappa value ranged from 0.90 to 0.99).
CONCLUSION
While mediotemporal atrophy detected using Hip-hop is universal across the whole AD age spectrum, parietal atrophy detected using PAS is worth rating only in early-onset AD. Hip-hop and PAS are very reliable MRI visual scales.

Identifiants

pubmed: 34633317
pii: JAD210372
doi: 10.3233/JAD-210372
pmc: PMC8673546
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1259-1266

Subventions

Organisme : NIA NIH HHS
ID : U01 AG024904
Pays : United States
Organisme : CIHR
Pays : Canada

Références

J Neurol Neurosurg Psychiatry. 1992 Oct;55(10):967-72
pubmed: 1431963
Neurobiol Aging. 2003 Jan-Feb;24(1):95-103
pubmed: 12493555
Behav Neurol. 2009;21(1):3-12
pubmed: 19847040
Neurobiol Aging. 2012 Mar;33(3):627.e1-627.e12
pubmed: 21596458
Dement Geriatr Cogn Disord. 2008;26(2):175-86
pubmed: 18698140
AJNR Am J Neuroradiol. 2005 Feb;26(2):333-40
pubmed: 15709131
Neuroimage. 2014 May 15;92:169-81
pubmed: 24521851
Neuroscience. 2021 Mar 1;457:283-293
pubmed: 33246061
Biomed Res Int. 2020 Sep 23;2020:5894021
pubmed: 33029517
Psychiatry Res Neuroimaging. 2019 May 30;287:70-74
pubmed: 31003044
J Alzheimers Dis. 2015;48(3):581-9
pubmed: 26402089
Neurology. 2003 Nov 11;61(9):1196-203
pubmed: 14610120
Neurobiol Aging. 2013 Aug;34(8):2014-22
pubmed: 23561509
J Neurol. 2006 Jun;253(6):794-800
pubmed: 16511646
AJNR Am J Neuroradiol. 2006 Aug;27(7):1454-8
pubmed: 16908557
Biochim Biophys Acta. 2012 Mar;1822(3):325-32
pubmed: 21839829
Curr Alzheimer Res. 2018;15(1):18-27
pubmed: 28891447
Curr Alzheimer Res. 2020;17(6):534-539
pubmed: 32851946
Eur Radiol. 2011 Dec;21(12):2618-25
pubmed: 21805370
PLoS One. 2014 Dec 12;9(12):e115174
pubmed: 25502906
J Neurol Neurosurg Psychiatry. 2000 Nov;69(5):630-5
pubmed: 11032615
Neurobiol Aging. 2017 Apr;52:167-182.e1
pubmed: 28317647
Brain. 2007 Mar;130(Pt 3):720-30
pubmed: 17293358
Alzheimers Res Ther. 2010 Aug 31;2(4):23
pubmed: 20807454
J Neurol Neurosurg Psychiatry. 2015 Nov;86(11):1225-33
pubmed: 25872513
Psychiatry Res Neuroimaging. 2016 Jun 30;252:26-35
pubmed: 27179313
Lancet Neurol. 2011 Mar;10(3):280-8
pubmed: 21185234
J Alzheimers Dis. 2020;73(4):1575-1583
pubmed: 31958089
Neurobiol Aging. 2010 Aug;31(8):1375-85
pubmed: 20447732
Neurologia (Engl Ed). 2018 May;33(4):244-253
pubmed: 26546285
J Alzheimers Dis. 2010;19(4):1401-8
pubmed: 20061618
Front Neurol. 2014 Jan 09;4:216
pubmed: 24409168
J Alzheimers Dis. 2021;79(1):237-247
pubmed: 33252076
Neurology. 2004 Feb 24;62(4):591-600
pubmed: 14981176
Neurology. 2001 Jul 24;57(2):216-25
pubmed: 11468305
J Alzheimers Dis. 2018;64(2):497-504
pubmed: 29889066
Front Aging Neurosci. 2017 May 09;9:117
pubmed: 28536518
Brain. 2016 Apr;139(Pt 4):1211-25
pubmed: 26936938
Neuroradiology. 2007 Dec;49(12):967-76
pubmed: 17955233

Auteurs

David Silhan (D)

Department of Neurology, Charles University, Third Faculty of Medicine, Prague, Czech Republic.

Olga Pashkovska (O)

Department of Neurology, Charles University, Third Faculty of Medicine, Prague, Czech Republic.

Ales Bartos (A)

Department of Neurology, Charles University, Third Faculty of Medicine, Prague, Czech Republic.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH